tenofovir alfenamide

also known as TAF

Developed for: HIV infectious disease
Investigated by: CONRAD · Centre Hospitalier Universitaire Vaudois · EuroVacc Foundation · Gilead Sciences · Imperial College London · Instituto Nacional de Saúde, Mozambique
+9 more
· International AIDS Vaccine Initiative · Karolinska Institutet · King's College London · Ludwig-Maximilians - University of Munich · MRC/UVRI and LSHTM Uganda Research Unit · Medical Research Council, South Africa · Muhimbili University of Health and Allied Sciences · National Institute for Medical Research, Tanzania · University College, London

today NCT04066881 · Ph 2

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04066881	Dec 2020 → Dec 2024	HIV infectious disease	MRC/UVRI and LSHTM Uganda Research Unit	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	tenofovir alfenamide	“Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗
Known as	TAF	“Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗